fbpx

Struggling with side effects after cancer treatment?

Learn how you can manage and alleviate your current side effects while actively working to prevent a relapse or secondary cancer using evidence-based, non-toxic therapies.

Click the orange button to the right to learn more.

Pulmonary Fibrosis- Non-Conventional Therapies

Share Button

Hi David- I was diagnosed in 2013 with pulmonary fibrosis and in early 2014 was told it was idiopathic pulmonary fibrosis (IPF). Next thing I found was I would need to carry around oxygen wherever I went and use it at home and while I slept.

I was given a couple of years. In 2018 I was told by a holistic nurse practitioner to try multivitamin herbal treatment because my condition was getting worse. I used the herbal formula in March 2018. My lifestyle has changed since all this began. I consume no alcohol, walk more than I used to and without oxygen, and am able to control my weight much better than before.

All of this has changed. I exercise and walk daily, play catch and dance with my grandchildren, I have used the organic remedy for over 4 month without any further usage or side effects .

I can only speak for myself, but I highly recommend evidence-based, non-conventional treatment for those who know the feeling of gasping for air as I did. Kent


Hi Kent-

I’ve been reading a lot about pulmonary fibrosis (PF) lately. Apparently PF is a fairly common “long covid” side effect from the covid sars virus.

I supplement with Life Extension N-Acetyl Cysteine. NAC enhances my quality of life as well according to the articles below. And I exercise moderately.

I also supplement with Life Extension Foundation Curcumin Elite. I highly recommend both of these supplements for pulmonary fibrosis.

David Emerson

  • Cancer Survivor
  • Cancer Coach
  • Director PeopleBeatingCancer

Recommended Reading:

 

 


Oral administration of curcumin ameliorates pulmonary fibrosis in mice through 15d-PGJ2-mediated induction of hepatocyte growth factor in the colon

“Oral administration of curcumin has been shown to inhibit pulmonary fibrosis (PF) despite its extremely low bioavailability. In this study, we investigated the mechanisms underlying the anti-PF effect of curcumin in focus on intestinal endocrine…

Together, curcumin promotes the expression of HGF in colonic fibroblasts and macrophages by activating PPARγ and CREB via an induction of 15d-PGJ2, and the HGF enters the lungs giving rise to an anti-PF effect…”

Efficacy of N-Acetylcysteine in Idiopathic Pulmonary Fibrosis

“CONCLUSIONS– The limited evidence currently available suggests that N-acetylcysteine has a significant effect only on decreases in VC and 6MWT and fails to significantly reduce changes in FVC, changes in DLco, adverse events, or death. N-acetylcysteine should, therefore, not be recommended for routine treatment of patients with IPF until additional high-quality RCTs have been performed. Our results need to be interpreted with caution because of the heterogeneity and low statistical power of the studies included in this meta-analysis…”

Hyperbaric oxygen therapy effects on pulmonary functions: a prospective cohort study

“Background: Oxygen toxicity is one potential side effect of hyperbaric oxygen therapy (HBOT). Previous small studies showed mild reductions in pulmonary functions reflecting reductions in small airway conductance after repetitive hyperbaric oxygen sessions. However, there are no updated data with well performed pulmonary tests that address the pulmonary effect of the currently used HBOT protocols.

The aim of this study was to evaluate the effect of HBOT on pulmonary functions of patients receiving the currently used HBOT protocol.

Methods: Prospective analysis included patients, 18 years or older, scheduled for 60 daily HBOT sessions between 2016 and 2018. Each session was 90 min of 100% oxygen at 2 ATA with 5 min air breaks every 20 min, 5 days per week. Pulmonary functions, measured at baseline and after HBOT, included forced vital capacity (FVC), forced expiratory volume in 1 sec (FEV1) and peak expiratory flow rate (PEF).

Results: The mean age was 60.36 ± 15.43 and 62.5% (55/88) were males. Most of the patients (83/88, 94.3%) did not have any pulmonary disease prior to inclusion and 30.7% (27/88) had a history of smoking.
Compared to baseline values, at the completion of 60 HBOT sessions, there were no significant changes in FEV1 (0.163), FEV1/FVC ratio (0.953) and FEF25–75% (0.423). There was a statistically significant increase though not clinically relevant increase in FVC (0.1 ± 0.38 l) and PEF (0.5 ± 1.4 l) with a 0.014 and 0.001 respectively.

Conclusion: Regarding pulmonary functions, repeated hyperbaric oxygen exposure based on the currently used HBOT protocol is safe. Surprisingly, there was a modest non clinically significant though statistically significant improvement in PEF and FVC in the current cohort of patients who were without chronic lung diseases.

Leave a Comment: